Repository logo
 

The Coagulation and Immune Systems are Directly Linked through the Activation of Interleukin-1α by Thrombin

Published version
Peer-reviewed

Change log

Authors

Burzynski, Laura 
Humphry, Melanie 
Wiggins, Katerina 

Abstract

Ancient organisms have a combined coagulation and immune system, and although links between inflammation and haemostasis exist in mammals, they are indirect and slower to act. Here we investigated direct links between mammalian immune and coagulation systems by examining cytokine proproteins for potential thrombin protease consensus sites. We found that interleukin (IL)-1α is directly activated by thrombin. Thrombin cleaved pro-IL-1α at a site perfectly conserved across disparate species, indicating functional importance. Surface pro-IL-1α on macrophages and activated platelets was cleaved and activated by thrombin, while tissue factor, a potent thrombin activator, colocalised with pro-IL-1α in the epidermis. Mice bearing a mutation in the IL-1α thrombin cleavage site (R114Q) exhibited defects in efficient wound healing and rapid thrombopoiesis after acute platelet loss. Thrombin-cleaved IL-1α was detected in humans during sepsis, pointing to the relevance of this pathway for normal physiology and the pathogenesis of inflammatory and thrombotic diseases.

Description

Keywords

Adaptive Immunity, Amino Acid Sequence, Animals, Blood Coagulation, Blood Platelets, Humans, Immune System, Immunity, Innate, Interleukin-1alpha, Keratinocytes, Macrophages, Mammals, Mice, Protein Precursors, Selection, Genetic, Sepsis, Sequence Alignment, Sequence Homology, Amino Acid, Thrombin, Thrombopoiesis, Wound Healing

Journal Title

Immunity

Conference Name

Journal ISSN

1097-4180
1097-4180

Volume Title

50

Publisher

Elsevier (Cell Press)
Sponsorship
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (RG/16/8/32388)
British Heart Foundation (FS/18/19/33371)
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (None)
Wellcome Trust (101692/Z/13/Z)
MRC (MR/P502091/1�)
British Heart Foundation (PG/16/11/32021)
British Heart Foundation (FS/18/19/33371)
British Heart Foundation (FS/18/56/34177)
This work was funded by British Heart Foundation Grants FS/09/005/26845, FS/13/3/30038, FS/18/19/33371 and RG/16/8/32388 to MC, RG/13/14/30314 to MB, the BHF Cambridge Centre for Research Excellence RE/13/6/30180, the Oxbridge BHF Regenerative Medicine Centre RM/13/3/30159, and the Cambridge NIHR Biomedical Research Centre.